Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY-Outcomes master protocol in high-risk MASLD
2025-522674-36-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 33
01
Overview
Phase 3, randomised, double-blind trial of tirzepatide and retatrutide in metabolic dysfunction-associated steatotic liver disease (MASLD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Time to first occurrence of any major adverse liver outcome and Composite major adverse liver outcomes endpoint. Planned start Mar 2026; status: authorised.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2025-522674-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522674-36-00.